Navigation Links
Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information
Date:11/26/2007

Landmark Meeting Dec. 6, 2007 to Address FDA's Next Big Challenge

Is the Food and Drug Administration Effectively Communicating Risk/Safety Information on Drugs and Devices to Physicians and the Public?

WASHINGTON, Nov. 26 /PRNewswire-USNewswire/ -- In 2005, FDA banned the use of a device that repairs damaged cells and treats cancer through electromagnetic waves, known as the Pap-Ion Magnetic Inductor (PAP-IMI), because of its apparent connection to patient injuries and death. However, on November 19, 2007 The Seattle Times reported that the PAP-IMI is still in use in at least five states, and that FDA has yet to issue a public statement about the risks linked with the device.

FDA's task is indeed daunting. A panel of experts will discuss and debate the issue of risk communication at a landmark colloquium, Communicating Risk/Safety Information: How FDA Is Meeting the Challenge, sponsored by the Food and Drug Law Institute (FDLI), Dec. 6, 2007, in Washington, D.C.

This meeting is the third in a series of colloquia sponsored by FDLI. Under its new strategic direction, FDLI is committed to using the colloquium series as a neutral forum to address the legal, regulatory, policy and practical implications of technological innovations affecting the food and drug industry.

As the public becomes more concerned about whether it's safe to take --- or stop taking --- their medications, FDA is making risk communication a top priority. The agency has formed an advisory committee on communication and implementing new Congressional requirements on risk evaluation. This program seeks to clarify what that means for those who must deal with adverse events and contraindications every day.

Colloquium attendees will receive:

-- Results of a study on how FDA handled the antidepressant drug controversy;

-- Analysis of the new risk evaluation and mitigation strategy (REMS) requirements;

-- Tips on developing world-class risk/safety and communications plans;

-- Vital information on FDA's new Risk Communications Advisory Committee;

-- An inside look at FDA's overall risk communications strategy from its Director of Risk Communication, Nancy Ostrove; and

-- Excerpts from FDA's Response to the IOM's Report on Drug Safety.

The expert panel includes:

-- Nancy Ostrove, Director, Risk Communication, FDA;

-- Randall Lutter, Deputy Commissioner for Policy & Planning, FDA;

-- Stuart Pape, Managing Partner, Patton Boggs;

-- Robert Dormer, Partner, Hyman Phelps & McNamara;

-- Grace-Marie Turner, President, Galen Institute;

-- Susan Newberry, Senior Vice President, Director, D.C Healthcare Practice, Ketchum Communications; and

-- Kelly Posner, Associate Professor, Columbia University.

Registration is $295 for FDLI members, $395 for non-members. Attendance is limited, so registrants are strongly urged to sign up early.

To register, visit http://fdli.org or call +1-800-956-6923 or +1-202-371-1420.

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field.


'/>"/>
SOURCE Food & Drug Law Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
2. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
3. LifeNet Health Establishes The Skin & Wound Allograft Institute
4. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
5. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
6. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
7. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
8. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
9. Bullying Prevention Institute Designed to Empower Change in Schools
10. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
11. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology: